Non opioid pain patches market
Market players continue to invest in manufacturing lidocaine patches, which would generate greater total return to shareholders (TRS). Benefits of lidocaine patches - superior topical effectiveness with minimal side effects and prolong transdermal drug release - are enabling their broader application. By 2029, lidocaine patches worth over US$ 3 Bn will be leveraged in treating chronic pain conditions. Influenced by these numbers, manufacturers are indulging in continuous R&D activities to develop lidocaine-based non-opioid pain patches.
128 views • 9 slides